AmBTU is new partner of TargetAMD

It is our pleasure to inform you that AmBTU from the Netherlands (STICHTING AMSTERDAM BIOTHERAPEUTICS UNIT) is new partner of the TargetAMD Consortium. Since AmBTU has the technology and the know-how to produce GMP grade plasmids, which are necessary for the TargetAMD clinical trial, the accession of this new partner to the Consortium is of great value. This will guarantee a successful transfer from laboratory to pharmaceutical quality, which will be realized by vector production according to GMP quality criteria.

30. January 2015
Categories: Target AMD